Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 189 | 37% |
| 2020 | 2 | 123 | 40% |
| 2021 | 3 | 89 | 43% |
| 2022 | 2 | 143 | 46% |
| 2023 | 2 | 167 | 50% |
| 2024 | 4 | 187 | 54% |
| 2025 from claims | – | 82 67–97 | 54% |
| 2026 forecast | – | 84 65–105 | 54% |
| 2027 forecast | – | 84 62–111 | 55% |
| 2028 forecast | – | 84 59–116 | 56% |
| 2029 forecast | – | 84 57–121 | 57% |
| 2030 forecast | – | 84 55–125 | 57% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Washington; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2024, 19% hospital outpatient, 81% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 23 | 583+5.4%/yr | +5.4%/yr | 0.2 | 32% | 500 in 2030−2.5%/yr |
| Arizona | 5 | 365+24%/yr | +24%/yr | 0.4 | 67% | 950 in 2030+17%/yr |
| Colorado | 9 | 330+20%/yr | +20%/yr | 0.6 | 11% | 570 in 2030+9.4%/yr |
| Idaho | 2 | 102+43%/yr | +43%/yr | 0.5 | 0% | 170 in 2030+8.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 74 | 2,603−5.2%/yr | −5.2%/yr | 3.31.0× | 17% | 2,650 in 2030+0.3%/yr |
| Lumbar fusion | 49 | 1,995−4.1%/yr | −4.1%/yr | 2.50.9× | 1% | 1,980 in 2030−0.1%/yr |
| Cervical fusion & disc arthroplasty | 12 | 886−6.9%/yr | −6.9%/yr | 1.10.9× | 11% | 890 in 20300%/yr |
| Kyphoplasty & vertebroplasty | 8 | 686−4.6%/yr | −4.6%/yr | 0.91.0× | 43% | 570 in 2030−2.9%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
SI-BONE leads with 99% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 3 companies reported engagement with Washington’s surgeons worth $229K in consulting, speaking, meals and travel tied to these products, about $57K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.